BioNeutral Group, Inc. (Stock Symbol: BONU) is a publicly traded specialty life science company, organized in 2003 to commercialize a novel combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses and spores. The formulations are green and include natural and common ingredients which are found in baby products and in the foods we eat. We combine these widely-used compounds in unique ways to create enhanced results.

Technology

BioNeutral has two different technology platforms which underpin the Ygiene™ and Ogiene™ formulations.

The formulation has several interesting characteristics/capabilities:

BioNeutral have developed the chemical technology and understand how to manipulate the formulations to address requirements that can vary the "kill time" (from seconds to minutes) and the breadth of kill (class of organisms – up to the most difficult to eradicate - spores) depending upon the needs of the market. 

The ingredients, when combined, have lower toxicity and far greater efficacy then anticipated. The formulations are
stable, non corrosive, non flammable and water soluble.

The formulations can be applied as a liquid, wet wipe, spray, mist/fog or foam/froth and can be applied to air, surface and water.

These exceptional properties of Ygiene™ are a result of the manner in which the chemical components are assembled and the resulting chemistry exhibited by these formulations.

• Ygiene™ has lasting power that far exceeds competitive products. In addition with a low initial active level, Ygiene™ is mild. For example, with a low initial level of actives Ygiene™ is not corrosive. In a very demanding iron corrosion test we have not found a commercial product which is as less corrosive than Ygiene™.

• Ygiene™ posses a unique balance of reactive chemistry and exceptional efficacy which far exceeds competitive antimicrobials

There are three categories of Ygiene formulations that are intended to serve a broad range of markets –

• Military/first responders/hospital sterilant/specialty industrial This is kill on contact for anthrax and all micro organisms. Application instructions and protection against direct contact with skin and eyes is required.

• Hospital/health care /mold/industrial applications include high level disinfection for hospitals and other health care facilities, eradication of mold and industrial cleaning in food preparation and other demanding environments (some application instructions and some protection against direct contact with skin and eyes is required). Will kill organisms in under 1 minute and will perform to a very high standard.

• Consumer products/light industrial/health care – General areas of the hospital, nursing home, physician or dental office. Very mild yet sporacidal, bactericidal and viracidal. Can be used as a superior skin sanitizer.

In each category, Ygiene produces results superior to those formulations presently in the market.

* These comparative tests are the results of our internal laboratory studies. We have not yet applied for EPA registration and we do not currently sell our Ygiene antimicrobial commercially.

OGIENE: BioNeutral's Ogiene formulations complex a broad range of dangerous and noxious chemicals and removes them from the air.  Our Ogiene™ formulations interact with the functional organic or inorganic groups of the harmful gases.

Our Ogiene™ formulations can complex, convert to salts or irreversibly react with toxic/odorous gases and render them harmless. These formulations are also water based and can be applied to air, surfaces and water. These gasses include:

Military/first responders/hospital sterilant/specialty industrial This is kill on contact for anthrax and all micro organisms. Application instructions and protection against direct contact with skin and eyes is required.

Mangement Team

Stephen J. Browand. Acting Chairman, President and CEO

With over 30 years of hands on business experience as a senior level executive in both start up emerging businesses and established international companies. Prior to joining BioNeutral, Mr. Browand served for ten years as the Chairman & CEO of the NYSS Group Ltd. a New York based multinational high profile security consulting firm. Prior he also served ten years as the President and CEO of Hachette Distribution Services USA (HDS/NA), a division of the Lagardere Group a public French multi-national conglomerate, as their North American representative. During his tenure with HDS/NA he oversaw the successful negotiation & completion of two major acquisitions that doubled the size of the group’s North American holdings & more than tripled their profitability. His extensive and diverse business experience spans the oceans from multiple sectors, including private, military and municipal. He started his career as an intelligence officer serving in the European theatre. He went on to sharpened his business acumen while holding executive positions at M.H. Lamston & as COO for Sock Shop International PLC a UK based company. He is well known for his visionary business acumen, participative management style & strict open door policy. A veteran of the United States Navy, Mr. Browand now lives with his family in a suburb of Long Island and is active in his community serving as a volunteer Special Police Lieutenant with the local Police Dept.

Dr. Andy Kielbania, the Chief Scientist

with over 35 years experience in the specialty chemical field, including coatings, adhesives, per­personal care, biotechnology and pharmaceuticals. He has previously held positions at Rohm and Haas where he assumed senior level positions in research and development. In 1993, Dr. Kielbania joined National Starch and Chemical Company (part of ICI) as research and development Director. Dr. Kielbania is the inventor on 21 patents and has published many technical articles. He is the winner of awards in new technology development to improve new business opportunities and also research and development improvements. He received his PhD in organic chemistry from the University of California at Berkeley and has post doctoral experience at Stanford University.

Barry M. Shereck, MBA, CPA, Financial Consultant/Certified Public Accountant of BioNeutral

Immediately prior to his arrival at the company, Mr. Shereck worked for several years as an independent financial and strategic consultant for a wide range of companies based in the US, Europe, and China. Prior to this, he served as Chief Financial Officer at Miavita, Inc., ON2 Technologies Inc., and Concord Camera Corp. He has also held key executive positions at Spring Investment Corp., Tyco Playtime, Inc., Citicorp POS Information Services, Inc., and Pioneer Electronic Corp. Mr. Shereck earned a B.Sc. degree from McGill University in 1965 and an MBA from Columbia University in 1969.

Board of Directors

Raj Pamani has worked with leading venture capital and financial institutions including: Josephthal & Co., Citibank (Private Bank) in Singapore, and Merrill Lynch where his responsibilities included structuring and implementing investments for offshore investment funds and assisting operating companies in operational and strategic planning. Mr. Pamani brings experience in negotiating and structuring private equity transactions. He was instrumental in taking public biotechnology companies including Medarex (NASDAQ: MEDX), Zonagen (ZONA), now RPRX, Texas Biotechnology (TXB), Ariad Pharmaceuticals (ARIA) and SciClone Pharmaceuticals (SCLN). Mr Pamani was Senior Vice President of the Amira Group. At Amira, he formed Strategic Alliances with Turner Group - cable television in the Middle East, LibanCell -telecommunication services, MTI Canada -mining efforts, International Petroleum Corporation - oil and gas, energy services, Coastal Corporation -oil and gas, Fortune Oil & Gas Company - oil and gas, Channel Oil - oil and gas Analyzing Merger and Acquisition Candidates. He also coordinated Relations with CeraTech -construction products, Teltronics -Harris communication switches, International Healthcare Investments Ltd. -medical and surgical supplies.

Suresh Relwani is a Principal in R.K. and Associates, Inc., a company specializing in environmental health and safety with over 28 years of experience as an environmental engineer and consultant. Prior to establishing RK and Associated, Mr. Relwani was a Principal Engineer at Harding Lawson Associates, where he managed the air quality group asd was responsible for air quality and odor services. His background includes activities in air emission source permitting, regulatory analysis, ar pollution control specifications, monitoring and modeling of atmospheric pollutants, odor control guidelines and strategies, and has published extensively on these topics. Mr. Relwani participates in several environmental committees that develop industry comments on evolving federal and state air quality regulations.

Scientific Advisory Board

Dr.Philip M. Tierno Jr. MS, PhD.

Dr. Tierno is the director of Clinical Microbiology and Diagnostic Immunology at New York University Langone Medical Center, and is Clinical Professor of Microbiology and Pathology at the New York University School of Medicine. He is a highly respected and world renowned microbiologist with more than 35 years of experience in the fields of Clinical and Medical Microbiology.

Dr. Tierno acts as a consultant to the office of Attorney General of the State of New York, Department of Health of the City of New York, National Institute of Health, Bethesda , MD, and the College of American Pathologists.  Dr. Tierno is also a member of the NYC Mayor's Task force on Bioterrorism and the United States representative to the International Hygiene Commission.

For more than 30 years Dr. Tierno has studied the effects of germicides and disinfectants on microbes.  His work in the field of microbiology has resulted in numerous articles and texts that have been published in the American Journal of Public Health, Journal of Clinical Microbiology, American Journal of Clinical Pathology, Lancet, Reviews of Infectious Diseases, JAMA, Journal of Infectious Diseases, etc., etc.  He is co-editor of a popular environmental book, "Staying Healthy in a Risky Environment".  He has authored recent books entitled "The Secret Life of Germs", "Protect Yourself Against Bioterrorism" and "Nuclear, Chemical and Biological Terrorism: Emergency Response and Public Protection".

Dr. Tierno is Co-founder and President of the "Foundation for Scientific Research in the Public Interest" (a non-profit organization).  Being considered one of the words' foremost scientific authorities in the area of environmental and medical microbiology and microbial ecology has resulted in numerous appearances as an expert on TV news, documentary, and investigative reports. Frequently referred to as “Dr. Germ” he has appeared on both local and network television shows such as 20/20, Oprah, Montel, Primetime,  Dateline, Nightline, Today, Good Morning America, to name just a few.

Dr. Tierno has been recognized extensively for his numerous contributions to the medical/scientific community.  He was bestowed the honor of Knighthood by the Sovereign Military and Hospitaler Order of Saint John Jerusalem, Knights of Malta.  In 2005 he was awarded the Il Leone de San Marco Award for lifelong achievements in Science and Medicine. He is a member of numerous other highly respected scientific societies and did his graduate studies at the New York University, where he was awarded an MS. in 1974 and his PhD. in 1977.

Vasu Kulkarni, PhD.

Dr. Kulkarni has a Doctorate in Environmental and Chemical Engineering and a Masters degree in Business Administration. He has over 20 years of both scientific and administrative industry experience with British Petroleum (BP). His direct responsibilities have included mergers and acquisitions, regulatory approval at the EPA, research and development, business to business marketing, channels of distribution and profitable new product/technology introduction. His is an experienced executive/scientist with a global view, extensive industry contacts and a history of building, leading and supporting a successful sales and marketing effort leading to over a quarter of billion dollars in sales.

Thomas C. Voltaggio

Mr. Voltaggio’s extensive career with the United States Environmental Protection Agency, entails thirty six years of comprehensive experience in multiple aspects of environmental management at the federal level, including executive level leadership, scientific and technical management, budgeting and analysis, enforcement and compliance, biological and chemical environmental emergency response, homeland security terrorism response processes and operations and information management and technology.

Tom directed all federal hazardous waste site remediation programs in the 6 state regional offices for 17 years. These included the Superfund, Brownfield, Resource Conservation and Recovery, Underground Storage Tank, Emergency Response and Oil Pollution programs. He brought about dozens of resolutions of complex environmental issues in air, water and hazardous waste fields with major corporations, state, local and federal governments through the use of detailed and profound knowledge of environmental programs and a well-developed skill in persuading environmental dispute resolution. In addition to the cleanup programs in the US, Mr. Voltaggio also assisted countries including Italy, Hungary, Poland, Czech Republic, India, Japan, Taiwan, South Africa and China.

Mr. Voltaggio managed the nation’s largest biochemical terrorism response when EPA was called upon to cleanup the Anthrax contamination on Capitol Hill in the fall of 2001; interacting on a daily basis with the highest levels of Agency and Congressional leadership. As a result of his leadership in responding to the Anthrax cleanup, Tom became the leading regional spokesperson for homeland security at EPA. He was also deployed to New Orleans as EPA's Senior Federal Official at the national response to Hurricane Katrina.

In 2006, Mr. Voltaggio founded an independent consulting firm, Voltaggio Consulting, LLC, where he consults various companies with domestic or international environmental and homeland security problems. He was also appointed by Governor Jon Corzine to the New Jersey Tidelands Resource Council. Tom has a Bachelor in Chemical Engineering from City College of New York, NY and a Masters in Management Science from Texas Christian University , Forth Worth, TX.

Dr. Donald Goldmann, M.D

Dr. Goldmann is Professor of Pediatrics at Harvard Medical School and Professor of Immunology and Infectious Diseases and Epidemiology at the Harvard School of Public Health. He teaches a Harvard College Freshman Seminar, “The Impact of Infectious Diseases on History and Society.” Dr. Goldmann's work has focused on preventing and controlling hospital-acquired infections. His applied research in the health services arena focuses on quality measurement and improvement, clinical practice guideline development and evaluation, assessment of parental perceptions of care, and patient safety.

Dr. Goldmann served on CDC’s Hospital Infection Control Practices Advisory Committee and chaired the taskforce that developed national guidelines for the use of a glycopeptide antibiotic, vancomycin. He and his colleagues used infection control as a model for quality assessment and improvement in developing countries including Brazil, Thailand, and Indonesia (development of validated methods to assess the structure, processes, and outcomes of infection control programs), Hungary and Poland (training of multidisciplinary QI teams and national surveillance), Colombia (reduction in C-section infections using QI interventions), Russia (national infection control training initiative and center-specific interventions), Ukraine (hospital assessments and microbiology laboratory capacity), Mexico, (use of QI methods to prevent pediatric nosocomial infection) and the Philippines (infection prevention collaborative and a clinical trial of interventions to reduce antibiotic resistance in academic NICUs).

Dr. Donald Goldmann is a graduate of Harvard Medical School. He completed an internship, residency, and fellowship at Massachusetts General Hospital. He served as an Epidemic Intelligence Service Officer of the Centers for Disease Control.

No info available.